MoveSurge

Eli Lilly spokesperson says company is carefully evaluating FDA drug-safety communication for GLP-1 RA and will respond promptly

Observed price moves

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.

Share